» Articles » PMID: 36685164

Effect of the Ligation and Reperfusion Timeframe on Maximal Ischemia-Reperfusion Injury in Diverse Rat Models

Overview
Date 2023 Jan 23
PMID 36685164
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Little is known about the effect that different time sequences for coronary ligation and reperfusion have on ischemic-reperfusion (IR) injury.

Objective: To investigate the relationship between the extent of IR injury and the timeframe for coronary ligation/reperfusion in three animal models.

Methods: Three rat models were used: normal Sprague-Dawley rats, diabetes mellitus (DM) rats, and fat rats. The rats in each model were divided into four groups based on the coronary ligation period (L): 30, 60, 120, and 180 min, and then divided into seven sub-groups based on the reperfusion period (R): 0, 30, 60, 120, 180, 270, and 360 min. R0 was the IR injury baseline for each sub-group. The hearts were harvested and stained with Evans blue and 2,3,5-triphenyl tetrazolium chloride dye to distinguish the different myocardial injury areas: area at risk (AAR) and myocardial necrosis. The difference between each subgroup and baseline (R0) for the necrotic area/AAR was calculated.

Results: In the normal rats, the highest IR injury differences compared with the baseline group occurred at L120, with a reperfusion time of > 180 min. The highest IR injury difference compared to the baseline group occurred at L30, with a reperfusion time of > 180 min in the DM rats and at L60R270, L120R180 in the fat rats.

Conclusions: IR injury, as induced by different coronary ligation and reperfusion time intervals, had diverse expression profiles in the different animal models. Optimal animal models with optimal coronary ligation/reperfusion protocols to achieve maximal IR injury will affect the results and interpretation of future studies.

Citing Articles

Comparison of the preconditioning effect of different exercise training modalities on myocardial ischemia-reperfusion injury.

Mohammadkhani R, Ranjbar K, Salehi I, Komaki A, Zarrinkalam E, Amiri P PLoS One. 2023; 18(12):e0295169.

PMID: 38051732 PMC: 10697534. DOI: 10.1371/journal.pone.0295169.

References
1.
Arai M, Lefer D, So T, DiPaula A, Aversano T, Becker L . An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol. 1996; 27(5):1278-85. DOI: 10.1016/0735-1097(95)00578-1. View

2.
Devereux R, Roman M, Paranicas M, OGrady M, Lee E, Welty T . Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000; 101(19):2271-6. DOI: 10.1161/01.cir.101.19.2271. View

3.
Mahaffey K, Puma J, Barbagelata N, DiCarli M, Leesar M, Browne K . Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999; 34(6):1711-20. DOI: 10.1016/s0735-1097(99)00418-0. View

4.
Apaijai N, Chattipakorn S, Chattipakorn N . Roles of obese-insulin resistance and anti-diabetic drugs on the heart with ischemia-reperfusion injury. Cardiovasc Drugs Ther. 2014; 28(6):549-62. DOI: 10.1007/s10557-014-6553-6. View

5.
Meng H, Maddaford T, Pierce G . Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function. Am J Physiol. 1993; 264(6 Pt 2):H1831-5. DOI: 10.1152/ajpheart.1993.264.6.H1831. View